New study: MOG relapse score not reliable for treatment choice

Credibility

Interest

Key Takeaway

A score designed to predict relapses in MOG antibody disease did not reliably predict who will relapse over three years in this UK patient group.

What They Found

Researchers tested a relapse-risk score (MOG-AR) in 284 people with MOG antibody disease to see if it could tell who would have another attack within three years. About 38% of people had a relapse in three years, but the score only weakly separated those who did and did not relapse. People with higher score grades tended to have more relapses (for example, grade 4 had 53% relapse), but the score often overestimated risk and missed many real outcomes. Overall accuracy was low — the statistical measure used to tell good from poor prediction was close to chance. The team concluded this score worked less well in this UK group and better tools are needed to decide treatment at the start of the disease.

Who Should Care and Why

Patients with MOGAD and their caregivers should care because decisions about starting long-term treatment often depend on how likely someone is to relapse — like deciding whether to lock the doors if break-ins are likely. If a prediction tool is unreliable, doctors and patients might make different choices about early treatment. Neurologists and MS/MOG specialists should also care because they need better, simple tools to guide treatment plans and avoid over- or undertreating people. Caregivers who help with medication, appointments, and monitoring symptoms will be affected if uncertainty leads to more frequent check-ins or changes in treatment. This finding is most useful for people making choices soon after diagnosis: it says we should be cautious relying only on this score when planning long-term care.

Important Considerations

This study looked at patients in one UK clinic and may not reflect every person with MOGAD, so results might differ in other places or groups. The score was developed in a different population (China), and differences between groups can make a tool less accurate elsewhere. Because the score only used a few clinical items (age, sex, first attack type, treatment), it may miss other important signals — so it shouldn’t be the sole reason to start or stop treatment.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics MS Progression Clinical Trials

Article Topics:

MOGADMyelin oligodendrocyte glycoprotein antibody-associated diseasePredictionRelapseRisk scoreValidation

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News